Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
teclistamab + daratumumab + lenalidomide
- Development stage
- Phase 3
- Lead developer
- Janssen Research & Development
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
Teclistamab + daratumumab + lenalidomide is a triple combination regimen under investigation and in clinical development for treating multiple myeloma, including newly diagnosed patients ineligible for stem cell transplant and those with relapsed or refractory disease. Teclistamab is a bispecific monoclonal antibody that binds B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells to redirect T-cell cytotoxicity toward malignant plasma cells. Daratumumab is an anti-CD38 monoclonal antibody that causes myeloma cell death via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis. Lenalidomide is an immunomodulatory small molecule that enhances immune response against myeloma cells and has anti-angiogenic and anti-proliferative properties. The combination aims to potentiate immune-mediated antimyeloma effects and deepen clinical responses. This triple regimen is being evaluated in multiple phase 1b and phase 3 clinical trials for efficacy and safety in various multiple myeloma settings[1][2][3][4][7].
- Other names
- Tec-DR
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)CD38 (Cluster of Differentiation 38)CRBN (Cereblon)
Beyond the preview
Go deeper on teclistamab + daratumumab + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on teclistamab + daratumumab + lenalidomide.